HAEMOSTATIX
Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen – a protein essential to the formation of clots. The peptide is coupled to different forms of solid support or soluble carriers to create both topical and systemic haemostats. This new technology platform is the basis of a pipeline of first-in-class products to treat various forms of bleeding in surgery, trauma and in leukaemic patients.
HAEMOSTATIX
Industry:
Biotechnology Clinical Trials Health Care Medical
Founded:
2003-01-01
Address:
Nottingham, Nottingham, United Kingdom
Country:
United Kingdom
Website Url:
http://www.haemostatix.com
Total Employee:
11+
Status:
Active
Contact:
+4401159124512
Total Funding:
6.98 M USD
Technology used in webpage:
SPF Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET Ajax Namecheap DNS
Similar Organizations
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Praxis Precision Medicines
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Current Employees Featured
Founder
Investors List
Albion Capital Group
Albion Capital Group investment in Venture Round - Haemostatix
Albion Capital Group
Albion Capital Group investment in Venture Round - Haemostatix
Albion Capital Group
Albion Capital Group investment in Venture Round - Haemostatix
Spark Ventures
Spark Ventures investment in Venture Round - Haemostatix
Catapult Ventures
Catapult Ventures investment in Venture Round - Haemostatix
Nesta Ventures
Nesta Ventures investment in Venture Round - Haemostatix
Wellcome Trust
Wellcome Trust investment in Venture Round - Haemostatix
Esperante Ventures
Esperante Ventures investment in Venture Round - Haemostatix
Spark Ventures
Spark Ventures investment in Series C - Haemostatix
Esperante Ventures
Esperante Ventures investment in Series C - Haemostatix
Official Site Inspections
http://www.haemostatix.com
- Host name: 185-151-30-164.ptr4.stackcp.net
- IP address: 185.151.30.164
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Haemostatix"
About us - Haemostatix
Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology …See details»
Haemostatix - Crunchbase Company Profile & Funding
Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company …See details»
Welcome to the Haemostatix website
Welcome to the Haemostatix website. This website is intended for professionals in the medical device and pharmaceutical industries only. The products described are not approved for …See details»
Home [www.haemostatix.com]
September 2015 - Haemostatix announces successful completion of proof of concept clinical trial of PeproStat Liquid in liver surgery patients. The clinical trial was carried out by four UK …See details»
Haemostatix 2025 Company Profile: Valuation, Investors
Haemostatix General Information Description. Developer of synthetic peptide-based hemostats intended to control bleeding. The company develops a liquid hemostat and transparent …See details»
Haemostatix - Raised $2.43M Funding from 12 investors - Tracxn
5 days ago List of Haemostatix's institutional investors. Royal Society of Chemistry, located in London (United Kingdom), made their first investment in Haemostatix on Jun 29, 2015 in its …See details»
Haemostatix - Company Profile - Tracxn
Mar 6, 2025 Haemostatix has developed a new class of peptide-based coagulant, or "haemostat", for the control of bleeding. The company has pioneered a new approach to …See details»
Haemostatix | VentureRadar
Haemostatix has developed a new class of active clotting agent, or "haemostat" for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a …See details»
Hemostatix - Crunchbase Company Profile & Funding
Hemostatix provides surgical precision, visualization, and control--Everything needs to achieve superior clinical outcomes. the Hemostatix thermal scalpel maximizes surgical technique and …See details»
Haemostatix - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Ergomed acquires Haemostatix - Global Venturing
Jun 9, 2016 Haemostatix was established in 2003 to commercialise a specific peptide sequence that helps with blood clotting. It was co-founded by Alison Goodall, professor of thrombosis …See details»
Haemostatix - VentureRadar
Similar Companies: Vega Therapeutics Inc. Unknown Privately Held We are focusing first on addressing the overlooked need in von willebrand disease [vwd] Vwd is the most common …See details»
Ergomed inks Haemostatix takeover to gain bleeding control assets
May 5, 2016 Ergomed (LON:ERGO) has struck a deal to buy Haemostatix and its pipeline of treatments for surgical bleeding. The agreement will give Ergomed its first wholly owned …See details»
Patents Assigned to HAEMOSTATIX LIMITED
Assignee: Haemostatix Limited Inventor: Greg Walker Biogel. Patent number: 9339584 Abstract: A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel …See details»
Haemostatix - Contacts, Employees, Board Members, Advisors
Haemostatix has developed a new class of active clotting agent, or "haemostat" for the control of bleeding. New. Resources. ... Experience the new Crunchbase, powered by AI . Organization. …See details»
Technology - Haemostatix
Haemostatix's topical haemostat, PeproStat, is composed of multiple peptides coupled to a soluble carrier, thus forming a highly active fibrinogen-binding site. When applied directly to …See details»
Catapult Venture Managers' portfolio company, Haemostatix, …
Nov 12, 2012 Haemostatix Ltd announces that it has received an additional £1.4 million Translation Award from the Wellcome Trust to continue development of its innovative …See details»
Haemostatix | VentureRadar
Similar Companies: Photobiotics United Kingdom Privately Held Photobiotics is a spin-out company from Imperial College, London, developing novel biologically-targeted photodynamic …See details»
Systemic Haemostatic Technology
Haemostatix has developed a systemic platelet substitute technology. An experimental prototype, HaemoPlax, has been developed that consists of microparticles linked to a fibrinogen-binding …See details»
Topical Haemostatic Technology
Haemostatix's topical haemostat, PeproStat, is based on coupling multiple fibrinogen-binding peptides to a soluble carrier, thus forming a highly active fibrinogen-binding site (Figure A). …See details»